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Abstract
Soft tissue sarcoma (STS) is a heterogeneous disease that arises from connective tissues. Clinical outcome of patients with
advanced tumors especially de-differentiated liposarcoma and uterine leiomyosarcoma remains unsatisfactory, despite
intensive treatment regimens including maximal surgical resection, radiation, and chemotherapy. MAP kinase-interacting
serine/threonine-protein kinase 1 and 2 (MNK1/2) have been shown to contribute to oncogenic translation via
phosphorylation of eukaryotic translation initiation factor 4E (eIF4E). However, little is known about the role of MNK1/
2 and their downstream targets in STS. In this study, we show that depletion of either MNK1 or MNK2 suppresses cell
viability, anchorage-independent growth, and tumorigenicity of STS cells. We also identify a compelling antiproliferative
efficacy of a novel, selective MNK inhibitor ETC-168. Cellular responsiveness of STS cells to ETC-168 correlates positively
with that of phosphorylated ribosomal protein S6 (RPS6). Mirroring MNK1/2 silencing, ETC-168 treatment strongly blocks
eIF4E phosphorylation and represses expression of sarcoma-driving onco-proteins including E2F1, FOXM1, and WEE1.
Moreover, combination of ETC-168 and MCL1 inhibitor S63845 exerts a synergistic antiproliferative activity against STS
cells. In summary, our study reveals crucial roles of MNK1/2 and their downstream targets in STS tumorigenesis. Our data
encourage further clinical translation of MNK inhibitors for STS treatment.
Introduction
Soft tissue sarcoma (STS) is a heterogeneous neoplasm with
more than 70 subtypes [1, 2]. Liposarcoma (LPS) and
leiomyosarcoma (LMS) represent two most frequent sub-
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(RMS) is the most common STS of children [5]. These three
types of STS show histological presentation resembling
partially the differentiation features of adipocytes, smooth
muscle cells, and skeletal muscle cells, respectively. Current
therapeutic modalities of STS mainly involve surgery,
radiation, and chemotherapy; however, outcomes of patients
with advanced STS remain unsatisfactory. More efforts are
needed to explore alternative therapeutic options.
MAP kinase-interacting serine/threonine-protein kinase 1
and 2 (MNK1/2) are two downstream kinases of p38
MAPK and MAPK/ERK kinase-extracellular signal-regu-
lated kinase (MEK-ERK) pathways, with their best-studied
function to phosphorylate eukaryotic translation initiation
factor 4E (eIF4E) at Ser209 site [6, 7]. To date, the onco-
genic roles of MNK1/2 and phosphorylated eIF4E have
been implicated in various cancers. For instance, depletion
of MNK1/2 in KIT-mutant melanoma cells inhibited tumor
progression through blocking translation of SNAI1 and
CCNE1 [8]. Intriguingly, suppression of either MNK or
eIF4E phosphorylation is well-tolerated without inhibitory
effects on global translation. Mice with either single or
double knockout of MNK1 and MNK2 were viable and
born without abnormalities [9]. Consistent with these find-
ings, small-molecule inhibitors targeting MNK1/2 (e.g.,
CGP57380, BAY1143269, eFT508, and SEL201) demon-
strated promising anticancer efficacy and desirable safety
[10]. Among these compounds, CGP57380 is widely used
as a tool compound of MNK inhibitor [11, 12].
BAY1143269 inhibited MNK1 activity and its downstream
factors including genes involved in cell cycle, survival,
immune response, and epithelial–mesenchymal transition
[13]. MNK1/2 inhibitor eFT508 is currently under clinical
trials in hematological malignancies [14]; it also inhibited
the translation of PD-L1 in a murine liver cancer model
which was driven by MYC and KRAS [15]. Notably, apart
from eIF4E-dependent oncogenic translation, MNK1/2
exert diverse roles in cancer-promoting pathways. MNK1/2
can phosphorylate a number of downstream substrates such
as hnRNPA1 [16] and SPRY2 [17, 18]. Active MNK1/2
engaged TELO2 to sustain mTOR1 activity and contributed
to rapamycin resistance in cancer cells [19]. In addition,
MNK1/2 enhanced transcription of ANGPTL4 through
peroxisome proliferator-activated receptor in melanoma
cells [20]. In contrast to their well-established role in
translation, impact of MNK1/2 on oncogenic transcription
remains poorly explored.
Both RAS-MAPK and PI3K-AKT-mTOR signalling
pathways are aberrantly elevated in STS, especially de-
differentiated LPS and uterine LMS [21, 22]. Crosstalk
between MNK1/2 and these two pathways implicates
MNK1/2 as a common targetable downstream node in
heterogeneous STS. The current study investigated func-
tional relevance of MNK1/2 and their downstream targets in
STS. By both genetic and pharmacological approaches, we
demonstrated the essential role of MNK1 and MNK2 in
soft-tissue sarcomagenesis, and identified E2F1, FOXM1,
and WEE1 as critical downstream effectors of MNK1/2.
Importantly, we also reported potent antiproliferative
properties of a novel MNK inhibitor ETC-168 against STS
cells. Co-inhibition of MNK1/2 and MCL1 yielded further a
synergistic anti-STS activity. Together, our study reveals a
targetable oncogenic dependency of STS cells on MNK1/2,
providing rationale for further development of MNK1/2-
targeted therapy.
Results
Elevated expression of MNK1 and MNK2 in STS cells
Expression and role of MNK proteins remain uncharacter-
ized in STS cells, although overexpression of either MNK1
or MNK2 has been reported in several human malignancies
[8, 23, 24]. To fill in the gap, we first examined protein
expression of MNK1 and MNK2 in a panel of STS cell
lines, including nine LPS cell lines (pleomorphic LPS:
LiSa-2; myxoid LPS: MLS402, MLS-1765; well-
differentiated LPS: T778, T1000, GOT3; de-differentiated
LPS: LPS141, LP6, Shef-DDLPS01) and eight LMS cell
lines (bone LMS: LMS1; vulvar LMS: SK-LMS-1; uterine
LMS: LMS117, SK-UT-1, SK-UT-1B, MESSA; soft-tissue
LMS: Shef-LMS01-w1, Shef-LMS01-ws). hTERT immor-
talized adipose-derived mesenchymal stem cells ASC52telo
and human primary uterine smooth muscle cells HUtSMC
were used as normal controls. MNK1 protein was moder-
ately elevated in most STS cells in comparison with non-
malignant cells. MNK2 showed a more pronounced
expression in about half of cancer cells than their respective
nonmalignant counterparts (Fig. 1a). In addition, phospho-
MNK1 (at Thr197/202, Thr255, and Thr385 sites) and
phospho-MNK2 (at Thr249 site) were markedly increased
across cancer cells, relative to ASC52telo and HUtSMC
cells (Fig. 1a). These results reveal an enhanced expression
of total and phospho-MNK proteins in STS cells.
MNK1 and MNK2 confer a proliferative potential on
STS tumorigenesis
To explore functional relevance of MNK1 and MNK2 in
STS cells, shRNA-mediated gene silencing approach was
employed to modulate their expression. Depletion of either
MNK1 or MNK2 markedly reduced the cell viability of
LPS141 (de-differentiated LPS), MESSA (uterine LMS),
and RH5 (RMS) cells (Fig. 1b, c and Supplementary Fig.
S1a, b). Consistently, defective expression of either MNK1
or MNK2 compromised colony-forming capability of these
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STS cells (Fig. 1d, e). Moreover, simultaneous targeting of
both MNK1 and MNK2 yielded an additive growth-
inhibitory effect on both cell viability and clonogenicity
(Supplementary Fig. S1c, d). Next, we examined involve-
ment of MNK1/2 in STS tumor growth in vivo. STS cells
stably expressing shRNAs against either MNK1 or MNK2
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developed significantly smaller xenografts in NOD scid
gamma (NSG) mice (Fig. 1f–h). Together, our observations
indicate that both MNK1 and MNK2 enforce growth of
STS in vitro and in vivo.
MNK kinase inhibitor ETC-168 exerts a potent
antiproliferative effect
Functional importance of MNK1/2 prompted us to investi-
gate whether MNK1/2 can be effective targets for STS
treatment. To this end, we studied a novel MNK kinase
inhibitor ETC-168 whose biochemical IC50 values against
MNK1 and MNK2 were as low as 23 and 43 nM, respec-
tively [25]. At the dose of 1 μM, ETC-168 achieved desir-
able inhibition of the kinase activity of MNK1 (58%) and
MNK2 (97%), suggesting that ETC-168 acts as a MNK2-
biased, dual-MNK inhibitor in cells. We screened the
antiproliferative efficacy of ETC-168 against a large panel
of 18 STS cell lines and compared with three additional
agents targeting either MNK1/2 (i.e., CGP57380 and
eFT508) or eIF4E activities (4EGI-1) [26] (Fig. 2a, b). In
general, ETC-168 showed a greater potency than the rest of
the agents (Fig. 2c). The concentrations of half maximal
inhibition of cell proliferation of ETC-168 were less than
10 μM in most cell lines other than LiSa-2, LMS117, and
the nonmalignant ASC52telo cells (Fig. 2c and Supple-
mentary Fig. S2a). For instance, in LPS141 and MESSA,
ETC-168 induced dose-dependent growth suppression and
inhibited 50% of cell viability at a dose of 5 μM, while other
inhibitors were less active (Fig. 2d). ETC-168 treatment
elicited a consistent increase of cells in G0/G1 phase among
LPS141, LP6, and MESSA cells in a dose-dependent
manner (Fig. 2e). In parallel, ETC-168 treatment decreased
cells of S and G2/M phases, while no significant induction
of sub-G1 cells was observed in all three cells. On the
contrary, ETC-168-insensitive LiSa-2 and LMS117 cells
were in general unresponsive to the treatment. These data
suggest that ETC-168 treatment inhibits cell proliferation
and cell cycle progression mainly through a cytostatic
effect. Based on IC50 values, LP6 and LPS141 represented
ETC-168 sensitive LPS cells, while MESSA, SK-UT-1, and
SK-UT-1B served as representative ETC-168 sensitive
uterine LMS cells (Fig. 2f, g). LiSa-2 and LMS117 were
considered as negative control lines whose IC50 values of
ETC-168 were over 30 μM (Fig. 2f, g).
MNK1/2 enforce eIF4E phosphorylation but have a
limited impact on translational regulation
As eIF4E is a well-documented substrate of MNK kinases, we
reasoned that phosphorylation of eIF4E at Ser209 site (p-4E)
may serve as an indirect readout of cellular responsiveness to
MNK inhibition. Indeed, simultaneous silencing of MNK1
and MNK2 by siRNAs potently suppressed p-4E, while single
knockdown of either MNK1 or MNK2 showed limited impact
(Fig. 3a). Hence, MNK1 and MNK2 have a synergistic
function to phosphorylate eIF4E in STS cells. Interestingly,
inhibition of MNK1/2 by ETC-168 elevated the expression of
MNK1/2 at both transcript and protein levels, suggestive of a
potential feedback mechanism via which STS cells turn on a
compensatory gene expression program upon kinase inhibition
(Supplementary Fig. S2b, c).
MCL1, an anti-apoptosis gene [27], has been previously
reported as a translational target of MNK1/2 and p-4E [28]. In
our study, we found that MCL1 was responsive to MNK1/2
inhibition in a subtype-specific manner. Either co-depletion of
MNK1/2 or ETC-168 treatment decreased MCL1 protein in
uterine LMS cells without any reduction in either MCL1
transcripts or protein half-life (Fig. 3a, b and Supplementary
Fig. S3a, b). However, neither protein nor mRNA level of
MCL1 responded to MNK1/2 knockdown in LPS141 cells
(Fig. 3a, b). Mirroring the phenotypes of genetic silencing,
ETC-168 abolished p-4E in both LPS141 and MESSA within
1 h, whereas it reduced MCL1 protein only in MESSA cells
independent of transcription (Fig. 3c, d). Ectopic over-
expression of eIF4E in MESSA cells can counteract the
inhibitory effect of ETC-168 on MCL1 (Fig. 3e).
Comparative study of three MNK kinase inhibitors
(ETC-168, CGP57380, and eFT508) indicated a uniform
inhibition of p-4E at 30 μM. 4EGI-1, an inhibitor of eIF4E-
eIF4G interaction, did not have this potency (Fig. 3f). In
terms of p-4E inhibition, ETC-168 and eFT508 showed a
comparable activity, while CGP57380 was less proficient
(Figs. 2b and 3f). As a subtype-specific translational target
of MNK1/2, MCL1 protein declined upon treatment with
ETC-168, eFT508, and 4EGI-1 in MESSA cells but not in
LPS141 cells (Fig. 3f and Supplementary Fig. S3c). Nota-
bly, albeit p-4E has been shown as a key factor to enhance
oncogenic translation function by MNK1/2, cellular
responsiveness of p-4E to MNK kinase inhibitors decoupled
from the growth-inhibitory effect of these compounds in
STS. At the dose of 30 μM, ETC-168 effectively suppressed
Fig. 1 MNK1 and MNK2 are required for the growth of STS cells
both in vitro and in vivo. a Western blot showing MNK1 and MNK2
protein expression in STS cells. b Verification of shRNA-mediated
knockdown of MNK1 and MNK2 by western blot in LPS141 cells.
Effects of MNK1 and MNK2 silencing on c cell viability and d
anchorage-independent growth of LPS141, MESSA, and RH5 cells. e
Defective colony formation of LPS141 cells in soft agar upon MNK1/
2 knockdown. Effects of MNK1 and MNK2 ablation on in vivo tumor
formation of f LPS141 (n= 8), g MESSA (n= 8), and h RH5 (n= 7)
cells. Cells were subcutaneously injected into the upper flanks of NSG
mice. After 3–4 weeks, xenograft tumors were harvested, weighed,
and photographed. Nil, no tumor growth. Data of c, d are shown as
mean ± SD from representative data out of three independent experi-
ments. Statistical significance is determined by unpaired two-tailed
Student t test. n.s. not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
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both p-4E and cell viability, whereas CGP57380 and
eFT508 showed minor impact on cell viability in spite of
p-4E inhibition (Figs. 2c and 3f). Together, these results
suggest involvement of alternative mechanism other than
p-4E-dependent translation in mediating the STS-promoting
activity of MNK1/2.
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ETC-168 suppresses phosphorylation of ribosomal
protein S6 (RPS6) in sensitive STS cells
To explore impact of ETC-168 on intracellular signalling
transduction, we performed a slide-based phospho-protein
array. Treatment of LPS141 cells with ETC-168 (10 μM, 8 h)
showed a sharp inhibition of p-RPS6 at Ser235/236 site which is
a well-recognized readout of mTOR activity (Supplementary
Fig. S4a). This finding was verified by western blot analysis
in various LPS and LMS cell lines (Supplementary Fig. S4b).
Both p-RPS6 and its upstream kinases (S6K: p70S6K and
p85S6K) were selectively downregulated by ETC-168 in a
dose-dependent manner in all sensitive STS cells but stayed
resistant in LMS117 and LiSa-2 cells (Supplementary Fig.
S4b, c). In contrast, p-4E was consistently inhibited by ETC-
168 across all tested LPS and ULMS cells (Supplementary
Fig. S4b). Therefore, reduced phosphorylation of RPS6 serves
as a reliable biomarker associated with cellular response to
MNK inhibitor ETC-168.
E2F1, FOXM1, and WEE1 are sensitive to MNK1/2
inhibition in STS
The surprising decoupling of p-4E inhibition from ETC-168-
induced growth suppression in STS cells promoted us to
explore alternative activity of MNK1/2 independent of
translational regulation. Notably, along with our study, we
found that expression of p-RPS6, E2F1, FOXM1, and
WEE1 protein was elevated significantly in de-differentiated
LPS cancer cells, relative to nonmalignant ASC52telo cells
(Fig. 4a). Remarkably, tumor-specific expression of these
proteins can be effectively blocked by ETC-168 treatment.
Further analysis of ETC-168 treatment revealed a marked
time-dependent reduction in protein/mRNA of E2F1,
FOXM1, and WEE1 in both LPS141 and MESSA cells
(Supplementary Fig. S5a, b). In addition, we examined
protein levels of several LPS141 tumor-promoting genes
(i.e., RUNX1, c-MYC, FOSL2, RUNX2, and SNAI2) after
ETC-168 treatment [29]. However, these proteins showed
either no or marginal response to ETC-168 (Fig. 4b). In
contrast, protein levels of E2F1, FOXM1, and WEE1 were
downregulated consistently by ETC-168 in drug-sensitive
STS cells after 24-h drug incubation (Fig. 4a, c). Silencing
of MNK1 and MNK2 also cooperatively decreased the
abundance of E2F1, FOXM1, and WEE1 proteins in
LPS141 cells (Fig. 4d). Of note, ETC-168 treatment also
reduced mRNA levels of E2F1, FOXM1, and WEE1 in a
dose-dependent manner in ETC-168-sensitive cells (Fig. 4e),
while neither protein nor mRNA expression of these targets
was downregulated by ETC-168 in LiSa-2 and LMS117
cells. MCL1 mRNA expression remained unchanged in all
above treatments (Supplementary Fig. S5c).
FOXM1 [30], E2F1 [31], and WEE1 [32] have been
implicated in the pathogenesis of human cancers, yet their
roles remain vague in STS. We next examined consequence
of genetic silencing of these genes in STS cells. Echoing the
observations from MNK1/2 knockdown (Fig. 1), depletion
of FOXM1, E2F1, and WEE1 attenuated the cell viability
and anchorage-independent growth of both LPS141 and
MESSA cells (Fig. 5a–c). Importantly, silencing of FOXM1
and WEE1 also impaired subcutaneous tumor formation by
STS cells (Fig. 5d, e). Together, these results support that
MNK1/2 sustain the expression of FOXM1, E2F1, and
WEE1 to promote STS.
MCL1 is a targetable dependency whose inhibition
potentiates anti-STS efficacy of ETC-168
Uterine LMS cells were in general more sensitive to ETC-
168 than LPS cells (Fig. 2f, g). Together with the obser-
vation that MCL1 is a uterine LMS-specific downstream
target of MNK1/2, we hypothesized that reduced MCL1
expression can synergize with other effects from MNK
inhibition to inhibit STS. To test this, we first examined the
functional importance of MCL1 in STS. Genetic knock-
down experiment demonstrated that MCL1 was essential for
the viability and clonogenicity of both LPS (LP6, LPS141)
and uterine LMS (SK-UT-1B, MESSA) cells (Fig. 6a–c).
Remarkably, pharmacological inhibition of MCL1 by
S63845, a small molecule with high binding affinity to the
BH3-binding groove of MCL1 [33], potently inhibited the
viability of MESSA, LPS141, and LP6 cells with IC50
values of 0.96, 0.25, and 0.26 μM, respectively (Supple-
mentary Fig. 6a). These data suggest that MCL1 is a tar-
getable growth dependency of STS cells. Next, we explored
the combinational potential of MCL1 inhibitor and MNK
inhibitor based on Bliss model [34]. In de-differentiated
Fig. 2 MNK inhibitor ETC-168 exerts a potent antiproliferative
activity against STS cells. a Chemical structure of MNK inhibitors
ETC-168, eFT508, and CGP57380, as well as eIF4E/eIF4G inhibitor
4EGI-1. b Effects of MNK/eIF4E inhibitors (5 μM, 24 h) on the pro-
tein expression of eIF4E in LPS141 and MESSA cells. c Heatmap
showing antiproliferative activities of ETC-168, CGP57380, eFT508,
and 4EGI-1 in 18 STS cell lines. WDLPS well-differentiated LPS,
DDLPS de-differentiated LPS, MLPS myxoid LPS, PLPS pleo-
morphic LPS, LMS leiomyosarcoma, ULMS uterine LMS, RMS
rhabdomyosarcoma. IC50 values were determined by MTT assay after
72-h treatment based on at least three independent repeats. d Dose-
dependent curves showing the response of LPS141 and MESSA cells
to ETC-168, CGP57380, 4EGI-1, and eFT508 treatment. e Cell cycle
analysis of LPS cells (LPS141, LP6, and LiSa-2) and uterine LMS
cells (MESSA and LMS117) in response to ETC-168 treatment (24 h).
Dose-dependent curves showing the response of f LPS cells (LP6,
LPS141 and LiSa-2) and g uterine LMS cells (SK-UT-1, SK-UT-1B,
MESSA, and LMS117) to ETC-168. Data of d–g are shown as mean
± SD from representative data out of three independent experiments.
Statistical significance of e is determined by one-way ANOVA. n.s.
not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
1856 X.-Y. Ke et al.
Fig. 3 MNK1/2 and eIF4E regulate MCL1 expression in a
subtype-specific manner. a Western blot showing effects of MNK1
and MNK2 silencing on eIF4E and MCL1 in LPS141 and MESSA
cells. b qPCR analysis of mRNA expressions of MNK1, MNK2, and
MCL1 in LPS141 and MESSA cells after siRNA treatment (48 h). c
Western blot showing the expression of eIF4E and MCL1 in LPS141
and MESSA cells in response to ETC-168 treatment (5 μM). d Tran-
script level of MCL1 in LPS141 and MESSA cells in response to
ETC-168 treatment (5 μM). e Expression of MCL1 in response to
eIF4E overexpression and ETC-168 treatment (24 h). Lysates were
derived from parental MESSA cells or MESSA cells stably expressing
HA-tagged wild-type eIF4E. f Protein levels of eIF4E and MCL1 in
LPS141 and MESSA cells upon treatment with ETC-168, CGP57380,
4EGI-1, and eFT508 (30 μM, 24 h). Data of b, d are shown as mean ±
SD from representative data out of three independent experiments.
Statistical significance is determined by either b two-tailed Student t
test or d one-way ANOVA. n.s. not significant; *p < 0.05; **p < 0.01;
***p < 0.001.
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LPS cells, S63845 and ETC-168 exhibited a strong,
synergistic growth-inhibitory effect in vitro, as evidenced
by a Sum Bliss Score above 240 in both LPS141 and LP6
cells (Fig. 6d). Additionally, in uterine LMS cells MESSA,
simultaneous inhibition of MCL1 and MNK1/2 achieved
synergism in inhibition of cell viability (Fig. 6d).
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Co-treatment of S63845 and ETC-168 induced pronounced
cleavage of Poly (ADP-Ribose) Polymerase 1 (PARP1) and
Caspase 3 in LPS141, LP6, and MESSA cells, indicative of
an enhanced apoptotic cell death (Fig. 6e and Supplemen-
tary Fig. 6b). However, no synergy of drug combo was
observed in ETC-168-insensitive LiSa-2 cells (Fig. 6d).
Hence, inhibition of MCL1 augments the efficacy of ETC-
168 in MNK1/2 inhibitor-responsive STS cells in vitro. To
explore activity of ETC-168 and S63845 in vivo, mice
bearing LPS xenografts were randomized into four groups
for drug treatment: (1) vehicle control; (2) ETC-168 treat-
ment (50 mg/kg, p.o., b.i.d.); (3) S63845 treatment (20 mg/
kg, i.p., q.d.); (4) Combination of ETC-168 and S63845
treatment (Supplementary Fig. 6c). Echoing our observa-
tions made from in vitro treatment, ETC-168 treatment
strongly inhibited p-4E in tumor grafts, while S63845
treatment stabilized MCL1 (Fig. 6f). Single agent treatment
with S63845 triggered a modest induction of cleaved-
PARP, while combination of ETC-168 and S63845 exerted
a robust synergy in activating the expression of both
cleaved-PARP and cleaved-Caspase 3. These data indicate a
promising bioavailability and in vivo activity of ETC-168/
S63845 combo in tumor-bearing mice, providing valuable
insights for follow-up studies of developing optimal deliv-
ery strategy, as well as improving dosing and schedule of
drug treatment.
Discussion
In this study, we provide the rationale and strategy for
targeting MNK1/2 in STS. Both MNK1/2 and their newly
identified downstream targets including E2F1, FOXM1, and
WEE1 enforce oncogenic potentials of STS cells. We
demonstrate that a novel, potent MNK inhibitor ETC-168
can effectively block p-4E and transcription of E2F1,
FOXM1, and WEE1, along with its antiproliferative activity
in STS cells. We further uncover p-RPS6 as a promising
biomarker associated with ETC-168 responsiveness, and
concordant inhibition of MCL1 as a favorable strategy for
drug combo (Fig. 7). In line with previous reports [23, 35–37],
our data support the role of MNK1 and MNK2 as onco-
genes and therapeutic targets. Both MNK1 and MNK2
proteins were elevated in many STS cell lines when com-
pared with nonmalignant controls. Activities of MNK1/2
are correlated positively with their expression levels, as
suggested by the inhibitory effect of MNK1/2 silencing on
p-4E (Fig. 3a). Of note, upregulation of phospho-MNK1/2
was also prevalent among STS cells. Since ERK1/2 and p38
have been shown as the major upstream regulators of
phospho-MNK1/2 [38, 39], elevation of phospho-MNK1/2
in sarcoma cells is likely resulted from hyper-activation of
mitogen-activated protein kinases in cancerous state.
Interestingly, MNK2 showed a higher degree of over-
expression than MNK1. MNK2 also exerted stronger reg-
ulatory effects on both p-4E and in vivo tumor expansion of
STS cells. Hence, MNK2 may play a dominant role to
maintain the steady level of p-4E in STS cells and to enforce
their tumorigenic potentials. This finding was consistent with
the notion that MNK1 behaves as a stress-responsive kinase
with a low basal activity while MNK2 has a higher basal
activity [9]. However, our data suggest that MNK1 silencing
alone is insufficient to block p-4E in STS cells, which is
different from previous observations that either MNK1 inhi-
bitor or MNK1 depletion suppressed the expression of p-4E
[13, 35]. Instead, simultaneous targeting of MNK1 and
MNK2 shows synergistic effect on p-4E. Importantly, Mnk1/
2 double knockout mice are viable and compatible with
normal development [40], while Mnk1/2-deficient cells are
refractory to oncogenic transformation. Since loss of MNK1/2
can be tolerated by normal cells, MNK1/2 are desirable
cancer targets for pharmacologic inhibition.
Strong genetic dependence of STS cells on MNK1/2
establishes the rationales for MNK-targeted therapy. Sev-
eral small-molecule inhibitors against MNK1/2 kinase
activity have been developed including CGP57380,
eFT508, BAY1143269, and SEL201. In this study, we
report the anti-STS activity of a newly developed dual
MNK1/2 inhibitor ETC-168. Our comparative evaluation of
ETC-168, CGP57380, and eFT508 revealed a superior
antiproliferative efficacy of ETC-168 against STS cells.
Both ETC-168 and eFT508 showed better capability to
inhibit p-4E than CGP57380. Reduction of p-4E was
observed within 30 min of treatment with ETC-168, sug-
gestive of a rapid target engagement. However, to our
surprise, growth-inhibitory effect of these compounds does
not correlate with their impact on p-4E. Inhibition of
MNK1/2 uniformly reduced p-4E in MNK1/2 inhibitor-
insensitive cells. These data implicate additional p-4E-
independent mechanism in growth suppression upon
MNK1/2 inhibition. Besides, our findings suggest that p-4E
is dispensable for STS cell viability.
Fig. 4 Inhibition of MNK1/2 decreases expression of E2F1,
FOXM1, and WEE1. a Differential expression of eIF4E, RPS6,
FOXM1, E2F1, and WEE1 in ASC52telo and de-differentiated LPS
cells in either the presence or absence of ETC-168 (24 h). b Effect of
ETC-168 on RUNX1, c-MYC, FOSL2, RUNX2 and SNAI2 proteins
in LPS141 cells. c Effect of ETC-168 (24 h) on E2F1, FOXM1,
WEE1, and MCL1 protein in STS cells. NC negative control cells.
d Effect of siRNA-mediated silencing of MNK1 and MNK2 on E2F1,
FOXM1, and WEE1 in LPS141 cells. e Response of E2F1, FOXM1,
and WEE1 transcripts to ETC-168 treatment (24 h). Black, blue, red,
and brown bars represent ETC-168 dosages of 0, 1, 5, and 10 μM,
respectively. Data of e are shown as mean ± SD from representative
data out of three independent experiments. Statistical significance
is determined by one-way ANOVA. n.s. not significant; *p < 0.05;
**p < 0.01; ***p < 0.001.
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As a known target gene of MNK1/2-eIF4E, MCL1
responded to MNK1/2 inhibitors only in uterine LMS cells.
Inhibition of MNK1/2-eIF4E showed a limited impact on
protein synthesis of MCL1 in LPS cells. Remarkably, cells
retaining MNK1/2-dependent expression of MCL1 were
more sensitive to MNK1/2 inhibition, suggesting that
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MCL1 inhibition synergizes with other growth-inhibitory
effects from MNK1/2 inhibitors. In support of this notion,
MCL1 inhibitor showed an encouraging activity to augment
the efficacy of ETC-168. The differential kinetics and
strength of cleaved-PARP and cleaved-Caspase 3 between
LP6 and LPS141 in response to ETC-168/S63845 combo
(Fig. 6e and Supplementary Fig. 6b) may be associated with
cell line-specific genetic backgrounds (e.g., steady levels of
anti-apoptotic proteins). Combination of MCL1 inhibitor
and MNK1/2 inhibitor is a promising strategy for further
therapeutic development.
We identify p-RPS6 as a responsive biomarker for
MNK1/2 inhibitor ETC-168. As a downstream target of
RPS6 kinases (p70S6K and p85S6K) and mTOR, p-RPS6
has been shown as a candidate biomarker to predict cellular
response to mTOR inhibitor [41]. Along with a reduction in
p-RPS6, combined application of MNK1/2 inhibitor and
mTOR inhibitor has shown synergism against glioma
growth [35]. Phospho-S6K levels were markedly down-
regulated by ETC-168 in drug-sensitive cells (LPS141,
LP6, SK-UT-1B, MESSA, and SK-UT-1), while both
p70S6K and p85S6K were less responsive to ETC-168 in
drug-insensitive cells (LiSa-2 and LMS117). These data
suggest that S6K inhibition may partially contribute to the
antiproliferative activity of ETC-168. So far, it remains
elusive how ETC-168 inhibits p-RPS6 in STS cells.
Nevertheless, the strong and selective inhibition of p-RPS6
by ETC-168 suggests that S6K activity can be effectively
compromised upon ETC-168 treatment in responsive STS
cells. In support of this observation, MNK1/2 also act as
inhibitors of DEPTOR-mTORC1 binding and stabilizers of
TELO2-mTORC1, thereby enhancing mTORC1 function
[19]. Additionally, MNK1/2 have been reported to regulate
S6K in a kinase-independent manner [42]. It is possible that
ETC-168 impairs p-RPS6 via either direct inhibition of
MNK1/2-mTOR-S6K signalling components or disruption
of MNK1/2 substrates which indirectly regulate RPS6
phosphorylation in STS cells. Inhibition of p-RPS6 may
synergize with that of p-4E in suppression of STS pro-
liferation. In addition to p-RPS6, basal expression of
MNK2 serves as another potential predictive marker for
ETC-168. Sarcoma cells with high expression of both
MNK1 and MNK2 (e.g., LPS141, LP6, MLS402, MESSA,
SK-UT-1, SK-UT-1B, and T778) were more responsive to
MNK inhibitors (Fig. 2c). Most of ETC-168-insensitive
cells expressed a smaller amount of MNK2 proteins, e.g.,
ASC52telo, LiSa-2, and LMS117. Further increase in
sample size will strengthen this observation.
Apart from p-4E-dependent translation, MNK1/2 have
been shown to regulate transcription of the oncogenic
ANGPTL4 [20]. We also uncover that MNK1/2 maintain
active transcription of three crucial STS-promoting genes,
i.e., FOXM1, E2F1, and WEE1. Notably, all three genes are
well known as drivers of mitotic cell cycle [43]. ETC-168
demonstrated a robust suppression of all three genes in
responsive cells, which was accompanied by a marked
disruption of cell cycle progression. A systematic exam-
ination of ETC-168-responsive transcriptome may help to
discover key transcriptional nodules/modulators mediating
the activity of MNK1/2. As our phospho-protein array
indicated a clean and specific activity of ETC-168 on
intracellular signalling transduction, it is unlikely that
MNK1/2 regulate gene transcription via signalling cross-
talk. Alternatively, MNK1/2 may participate in gene tran-
scription by regulating transcription apparatus, nuclear
transport (e.g., nucleoporins and karyopherins [44, 45]) or
transcription factors (e.g., peroxisome proliferator-activated
receptors [46]). ETC-168 can be used as a useful compound
and surrogate tool to block oncogenic expression of E2F1,
FOXM1, and WEE1 in human cancers. ETC-168 may be
useful for drug combination, especially for cases that
genetic inhibition of these genes has been proven syner-
gistic with other therapeutic agents. As both FOXM1 and
E2F1 are master transcription factors in human cancer,
inhibition of MNK1/2-dependent expression of FOXM1
and E2F1 will have a broad impact on transcriptome.
Collectively, this study reveals a druggable genetic
dependency of STS cells on MNK1/2 and their novel
downstream targets including E2F1, FOXM1, and WEE1.
Pharmacologic inhibition of MNK1/2 can impair both
expression of transcriptional targets and p-4E-dependent
oncogenic translation. Therapeutic targeting of MNK pro-
teins holds the promise for STS treatment.
Materials and methods
Cell culture
Human embryonic kidney cell line HEK293T, LMS cell lines
LMS1, LMS117, SK-UT-1, and SK-UT-1B were maintained
in Dulbecco’s Modified Eagle Medium (DMEM, Biowest).
SK-LMS-1 cells were cultured in Minimum Essential Media
(MEM, Gibco). LMS cell line MESSA was maintained in
McCoy’s 5 A (Modified) Medium (McCoy, GibcoTM).
Fig. 5 E2F1, FOXM1, and WEE1 are critical for soft-tissue sar-
coma growth. a Verification of shRNA-mediated silencing of E2F1,
FOXM1, and WEE1 in LPS141 and MESSA cells. b, c Effect of
shRNA-mediated silencing of E2F1, FOXM1, and WEE1 on: b via-
bility and c colony-forming ability of LPS141 and MESSA cells.
d, e Effects of shRNA-mediated silencing of FOXM1 (n= 8 for each
cell line) and WEE1 (n= 8 for each cell line) in LPS141 and MESSA
cells on their tumorigenic ability in immunodeficient mice. Nil, no
tumor growth. Data of b and c are shown as mean ± SD from repre-
sentative data out of three independent experiments. Statistical sig-
nificance is determined by two-tailed Student t test. n.s. not significant;
*p < 0.05; **p < 0.01; ***p < 0.001.
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Adipose mesenchymal stem cell ASC52telo was cultured in
mesenchymal stem cell basal medium supplemented with
mesenchymal stem cell growth Kit (ATCC). Human primary
uterine smooth muscle cell (HUtSMC) was maintained in
vascular cell basal medium supplemented with vascular
smooth muscle cell growth kit (ATCC). Shef-DDLPS01,
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Shef-DDLPS02, Shef-LMS01-w1, and Shef-LMS01-ws cells
were kindly provided by Drs Karen Sisley and Abdulazeez
Salawu [47]. RH5 was a kind gift from Dr Peter Houghton.
LP6 and LPS141 cells were provided by Dr Christopher DM
Fletcher [48]. MLS402, MLS-1765, and GOT3 cells were
generously provided by Dr Pierre Åman [49–51]. T778 and
T1000 cells were gifts from Dr Florence Pedeutour. 402-91/
ET [52], FU-DDLS-1 [53], and LiSa-2 [54] cells were gifts
from Dr Eugenio Erba, Dr Jun Nishio, and Dr Peter Möller,
respectively. MESSA, SK-UT-1, and SK-UT-1B cells were
kindly provided by Dr Stefan Fröhling. LMS117 and LMS1
were provided by Dr Raphael Pollock [55]. SK-LMS-1 was
generously provided by Omid Khorram. LMS cell lines (Shef-
LMS01-w1, Shef-LMS01-ws), alveolar RMS cell line RH5
and all LPS cell lines were maintained in Roswell Park
Memorial Institute medium 1640 (RPMI-1640, Biowest). All
of the above-mentioned cancer cell lines were cultured in
respective media supplemented with 10% fetal bovine serum
(FBS, Biowest) and 1% penicillin-streptomycin (Gibco). Cells
were grown in a humidified incubator with 5% CO2 at 37 °C.
All LPS cell lines have been authenticated by STR analysis
with the Geneprint 10 System Kit (Promega) and tested
negative for mycoplasma contamination.
Plasmids and chemicals
All shRNA vectors (Supplementary Table S1) were
cloned into pLKO.1 lentiviral vector. SHC002 was used
as non-targeting control (NT). Either puromycin (Sigma-
Aldrich) or blasticidin (Life Technologies) was used to
select stable knockdown cell lines. pHAGE-Flag-HA-
eIF4E-WT plasmid was a gift from Rebecca Lock [56].
siRNAs targeting MNK1 and MNK2 were purchased
from Dharmacon. RNAiMAX (Life Technologies) was
used to transfect siRNAs. ETC-168 was kindly provided
by Experimental Drug Development Centre (EDDC),
A*STAR, Singapore; CGP57380, eFT508, 4EGI-1,
Cycloheximide, and S63845 were purchased from
Abcam, MedChemExpress, Tocris Bioscience, Sigma-
Aldrich, and Chemietek, respectively.
Cell viability assay
Cell viability was detected by MTT (3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly,
STS cells were seeded in 96-well plates with 2000–3000
cells/well and then cultured for 72 h under indicated treat-
ments. At the end of experiment, 10 µL MTT substrate
(Sigma-Aldrich) was added into each well followed by 3-h
incubation. MTT substrate was then removed. Cells were
lysed by addition of 100 µL MTT stop solution. Absorbance
at 570 nm was measured using a Tecan microplate reader.
Soft agar colony formation assay
Soft agar colony formation assay was used to evaluate the
anchorage-independent growth of STS cells. In brief, in
each assay well of a 12-well plate, bottom layer was made
by 500 µL of DMEM or RPMI medium containing 10%
FBS and 0.5% agarose. Top layer was made by mixture of
1000–5000 STS cells and 500 µL of culture medium con-
taining 10% FBS and 0.4% low melting agarose. Plates
were put into a 4 °C freezer for 25 min followed by addition
of 2 mL/well of complete medium. Plates were kept in a
humidified incubator with 5% CO2 at 37 °C. After two to
three weeks, colonies were stained with 0.01% crystal violet
in 4% paraformaldehyde, and photographed using a dis-
section microscope.
Xenograft assay
All animal experiments were conducted in accordance with
ethical approval from the NUS Institutional Animal Care
and Use Committee. In vivo tumorigenicity of genetically
modified STS cells was accessed by subcutaneous xenograft
assay. NSG mice (6- to 8-week-old) were used in this study.
Indicated number of cells were mixed with 100 µL of PBS/
Matrigel (BD Biosciences) solution (1:1) and subsequently
injected subcutaneously into dorsal flank of recipient mice.
For in vivo drug treatment, mice bearing palpable LP6
xenografts were randomized into four groups after one-
week implantation. ETC-168 was given by oral gavage at a
dose of 50 mg/kg (100 µL, Ora-Plus Oral Suspending
Vehicle, Paddock Laboratories), twice a day for 2 days.
S63845 was given by tail vein injection at a dose of 20 mg/
kg (100 µL, 5% Solutol Vehicle), once a day for 2 days.
Mice were sacrificed at the experimental endpoint for tumor
harvest and subsequent protein extraction.
The sample sizes of mice in each experimental group
were not based on statistical methods but on experience.
The number of mice in each group had been described in
the figure legends. No animals were excluded from analysis.
No specific randomization and blinding methods were
performed for all animal studies.
Fig. 6 Inhibition of MCL1 synergizes with ETC-168 against STS
cells. Effect of MCL1 ablation on: a viability and b anchorage-
independent growth of STS cells. c Verification of shRNA-mediated
silencing of MCL1. d Drug matrix heatmap showing the inhibitory
impact and Delta Bliss Score upon ETC-168 treatment in combination
with S63845 in LP6, LPS141, MESSA, and LiSa-2 cells. Repre-
sentative matrix heatmap grid was showed from three independent
experiments. e, f Western blot showing the effect of ETC-168 and
S63845 (24 h) on expression of eIF4E and proteins related to apoptosis
in e STS cells in vitro and f LP6 tumor grafts in vivo. Data of a and b
are shown as mean ± SD from representative data out of three inde-
pendent experiments. Statistical significance is determined by two-
tailed Student t test. n.s. not significant; *p < 0.05; **p < 0.01; ***p <
0.001.
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Western blot assay
Cells were lysed with lysis buffer (50 mM Tris pH 8.0,
420 mM NaCl, 5% glycerol, 0.5% NP40, 1 mM EDTA)
supplemented with 1 mM DTT, 1 mM phenylmethylsulfo-
nyl fluoride (PMSF), 1 mM MgCl2, DNase (1:500, Thermo
Fisher Scientific), 1× protease inhibitor cocktail (Roche)
and 1× phosphatase inhibitor cocktail (Roche) for 30 min on
ice. For detection of total and phospho-MNK1/2 proteins,
cells were lysed by a modified lysis buffer (50 mM Tris pH
7.6, 150 mM NaCl, 0.2% NP-40, 2 mM EDTA) supple-
mented with 1 mM DTT, 1 mM PMSF, 1× protease inhi-
bitor and 1× phosphatase inhibitor. Proteins from xenograft
tumors were extracted by 1.2× RIPA buffer supplemented
with 1 mM DTT, 1 mM PMSF, 1× protease inhibitor and 1×
phosphatase inhibitor. Protein concentration was deter-
mined by Bradford assay. Western blot assay was carried
out following a standard protocol. Quantification of western
blot bands was done by ImageJ. Primary antibodies are
listed in Supplementary Table S2.
RNA preparation and real-time quantitative PCR
(qPCR)
Total RNA was isolated using RNeasy Kit (Qiagen,
74106) according to the manufacturer’s instructions.
Extracted RNA was treated with DNase and subjected to
reverse transcription using RevertAid RT Reverse Tran-
scription Kit (Thermo Fisher Scientific). qPCR was per-
formed using Kapa SYBR fast qPCR Master Mix (KAPA
Biosystems) on a 7500 Real-time PCR System (Applied
Biosystems). qPCR primers are listed in Supplementary
Table S3.
Cell cycle analysis
STS cells were seeded in a 6 cm plate. After drug treatment
for indicated concentrations and durations, cells were har-
vested and fixed in 70% ethanol at 4 °C overnight. Then
cells were washed with PBS and resuspended in 40 mg/mL
propidium iodide solution with RNase. Samples were
incubated at 37 °C for 30 min in the dark, followed by DNA
content analysis using LSR II Flow Cytometer System (BD
Biosciences).
Phospho-Kinase protein array
The Phospho-Kinase protein array was conducted using the
PathScan® RTK Signaling Antibody Array Kit (7949S, Cell
Signaling Technology) according to the manufacturer’s
instructions. LPS141 cells were treated with either DMSO
or 10 μM ETC-168 for 8 h.
Fig. 7 Graphical summary of
MNK1/2 function in STS and
rationale for co-targeting
MNK1/2 and MCL1. MNK
inhibitor ETC-168 is able to
disrupt both phospho-eIF4E axis
and MNK1/2-dependent
transcriptional regulation of
E2F1, FOXM1, and WEE1.
Blockage of MCL1 activity
synergizes with MNK1/2
inhibition against STS cells.
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Statistical analysis
Bliss model was used to quantify the combination effect of
two drugs. “Bliss expectation” formula is (A+ B− A× B),
where A and B represent the growth inhibition of drug A
and B at a given dose. “Delta Bliss” is the difference
between real growth inhibition and Bliss expectation of the
combination of drug A and B at the same dose. “Sum Bliss
Score” is the sum of Delta Bliss across whole dose matrix.
Statistical analyses were performed using GraphPad Prism.
The data met the assumptions of the tests and all data were
presented as mean ± SD. Statistical analysis was reported
using either two-tailed Student’s t test or one-way ANOVA
between control group and experimental group. n.s., not
significant; *P < 0.05; **P < 0.01; ***P < 0.001.
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